Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) Share Price Hits Fresh 52-Week High
- August 18, 2026
- Posted by: Harsh Piplani
- Category: News
Glaxosmithkline Pharmaceuticals Ltd. Share Price rose 6.20% to Rs 2,867.15 and touched a fresh 52-week high of Rs 2,876.55. Market capitalisation stood at Rs 45,554.98 crore.
Glaxosmithkline Pharmaceuticals Ltd. Share Price moved up to Rs 2,867.15 on 18 August 2026, a gain of 6.20% or Rs 167.35 from the previous close of Rs 2,699.80, and the stock touched a fresh 52-week high of Rs 2,876.55. The company’s market capitalisation stood at Rs 45,554.98 crore, placing it among the larger names in the Healthcare space.
This Glaxosmithkline Pharmaceuticals Ltd. Share Price Today move is notable because it combines a sharp single-session rise with a new one-year high. The supplied data confirms the price event clearly: the stock opened at Rs 2,675.65, traded as low as Rs 2,675.65, and climbed to the session high of Rs 2,876.55. Turnover for the session stood at Rs 3.25 crore with volume of 11,320 shares.
For investors following Glaxosmithkline Pharmaceuticals Ltd. Stock News, the key point is straightforward. The verified data confirms a strong price move and a fresh 52-week peak, but it does not establish a company-specific catalyst for why the stock is rising today. That leaves market participants focusing on price action, valuation, profitability metrics and sector positioning. In this Univest stock analysis, the next areas to monitor are whether the stock holds near this yearly high, how its valuation compares with Healthcare benchmarks, and how its profitability profile stacks up against peers.
Glaxosmithkline Pharmaceuticals Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,867.15 |
| Previous Close | Rs 2,699.8 |
| Today's Change | +Rs 167.35 (+6.2%) |
| Day Open | Rs 2,675.65 |
| Fresh 52-Week High | Rs 2,876.55 |
| Day Low | Rs 2,675.65 |
| Current Volume | 11,320 |
| Turnover | Rs 3.25 crore |
| Market Capitalisation | Rs 45,554.98 crore |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) traded at Rs 2,867.15. versus the previous close of Rs 2,699.8, a rise of 6.2%. The stock opened at Rs 2,675.65, reached Rs 2,876.55, touched Rs 2,675.65. Reported volume was 11,320.
Glaxosmithkline Pharmaceuticals Ltd. Share Price Today reflects a strong upward session, with the stock rising from Rs 2,699.80 at the previous close to Rs 2,867.15, while also recording a fresh 52-week high of Rs 2,876.55. The session’s open and low were both Rs 2,675.65, showing that the stock rebounded from the day’s starting level and moved decisively higher through the session.
From a pure price action perspective, the stock added Rs 167.35 in a single day, equivalent to 6.20%. The intraday range between the low of Rs 2,675.65 and the high of Rs 2,876.55 was wide, showing strong movement within the session. The current price of Rs 2,867.15 also leaves the stock very close to the day’s high, which is often watched closely in Share Market Today activity because it suggests the gains were largely retained into the latter part of trading.
Volume stood at 11,320 shares and turnover was Rs 3.25 crore. For Glaxosmithkline Pharmaceuticals Ltd. Share News, those figures matter because they show that the move was accompanied by active traded value, even though the supplied data does not provide an average-volume benchmark for a fuller volume analysis. In Stock Market Today terms, GLAXO has entered the list of 52 Week High Stocks and Market Movers because the price event is confirmed by session data rather than by end-of-day narrative alone.
For readers tracking Glaxosmithkline Pharmaceuticals Ltd. Share Price Live and daily Stock Updates, the immediate takeaway is that the stock has broken to a fresh one-year high and is now being judged not just on momentum, but also on whether the underlying fundamental profile supports sustained investor attention. That brings the discussion to Glaxosmithkline Pharmaceuticals Ltd. Fundamental Analysis.
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 45,554.98 crore |
| P/E Ratio | 170.32x |
| P/B Ratio | 0.42x |
| ROE | -2.89% |
| ROCE | -0.26% |
Glaxosmithkline Pharmaceuticals Ltd. was valued at a P/E ratio of 170.32x, a P/B ratio of 0.42x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 170.32x |
| Benchmark Median P/E | 21x |
| Benchmark Average P/E | 49.19x |
| Benchmark P/E Range | 0x to 1,598.54x |
| Company P/B Ratio | 0.42x |
| Benchmark Median P/B | 1.9x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.92% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.29% |
| Company Market Capitalisation | Rs 45,554.98 crore |
| Benchmark Median Market Cap | Rs 136.28 crore |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) is classified under sector: Healthcare.
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a P/E ratio of 170.32x, which is above the benchmark median of 21x, a difference of +711.05%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a ROE of -2.89%, which is below the benchmark median of 10.92%, a difference of -126.47%. Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a ROCE of -0.26%, which is below the benchmark median of 13.29%, a difference of -101.96%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,985.15 | 170.32 | 0.42 | -2.89 | -0.26 |
| Beta Drugs Ltd. | BETA | 2,827.67 | 65.02 | 10.29 | 18.65 | 22.17 |
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 2,645.37 | 47.53 | 1.82 | -0.78 | 8.31 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,562.17 | 33.62 | 6.93 | -2.6 | 16.92 |
| Fredun Pharmaceuticals Ltd. | FREDUN | 2,559.68 | 54.85 | 8.19 | 11.42 | 13.15 |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a P/E ratio of 170.32x compared with the displayed peer median of 54.85x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of -0.78% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a market capitalisation of Rs 45,554.98 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Glaxosmithkline Pharmaceuticals Ltd.
The stock is attracting attention because verified market data shows a clear event and a meaningful re-rating point for traders and long-term market observers alike.
- Fresh 52-week high: The stock touched Rs 2,876.55, its new one-year high.
- Strong daily move: Glaxosmithkline Pharmaceuticals Ltd. Share Price Today rose 6.20% or Rs 167.35 from the previous close.
- Closing near session high: The current price of Rs 2,867.15 remained close to the day’s peak.
- Large market cap: The company’s market capitalisation of Rs 45,554.98 crore makes it a sizeable Healthcare stock in market terms.
- Valuation contrast: P/E of 170.32 is above sector median and average, while P/B of 0.42 is below both benchmark levels.
- Profitability watchpoint: ROE of -2.89 and ROCE of -0.26 are below sector benchmark readings and below most supplied peers.
About Glaxosmithkline Pharmaceuticals Ltd.
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) is a listed company tracked in the Healthcare sector. In the supplied market datasets, it appears alongside broader Healthcare businesses and pharmaceutical-focused peers, making it relevant to investors who follow sector rotation, valuation differences and stock-specific price action in healthcare counters.
For market participants looking at Glaxosmithkline Pharmaceuticals Ltd. Company News, the most reliable company context available here is its sector classification, symbol and listed-market profile. The stock’s market cap of Rs 45,554.98 crore makes it significantly larger than the peer names supplied in the comparison set, which shapes how investors may interpret its movement relative to smaller healthcare companies. In the current session, GLAXO has become one of the Healthcare names in focus after reaching a fresh yearly high, placing it on the radar of those monitoring Stock Performance, valuation gaps and market trends within the Indian Stock Market.
Track Glaxosmithkline Pharmaceuticals Ltd. Share Price on Univest
Use Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors tracking Glaxosmithkline Pharmaceuticals Ltd. Share Price can use Univest to follow live share price movements, 52-week levels, valuation ratios, market capitalisation, sector comparisons and broader stock analysis. Univest also helps users monitor Glaxosmithkline Pharmaceuticals Ltd. Share Price Today alongside updated market insights and structured company data.
For readers following Glaxosmithkline Pharmaceuticals Ltd. Stock News and Glaxosmithkline Pharmaceuticals Ltd. Shareholding Pattern trends across the market, Univest offers a single place to review price action, fundamental ratios, peer positioning and key benchmark data without relying on unverified narratives. That makes it easier to keep track of fresh highs, price behaviour and financial context as new data emerges.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Glaxosmithkline Pharmaceuticals Ltd. Share Price today?
Ans. Glaxosmithkline Pharmaceuticals Ltd. Share Price was Rs 2,867.15 on 18 August 2026. The stock was up 6.20% or Rs 167.35 from the previous close of Rs 2,699.80 and traded close to its session high.
Why is Glaxosmithkline Pharmaceuticals Ltd. in stock news today?
Ans. Glaxosmithkline Pharmaceuticals Ltd. Stock News is active because the stock hit a fresh 52-week high of Rs 2,876.55 during the session. The supplied data confirms the price breakout, though it does not identify a company-specific catalyst.
What was the fresh 52-week high for GLAXO?
Ans. GLAXO touched a fresh 52-week high of Rs 2,876.55 on 18 August 2026. The current price was Rs 2,867.15, keeping the stock very near its yearly peak during the trading session.
How much did Glaxosmithkline Pharmaceuticals Ltd. gain today?
Ans. The stock gained Rs 167.35 in absolute terms, which translated into a 6.20% rise over the previous close of Rs 2,699.80. That move pushed Glaxosmithkline Pharmaceuticals Ltd. Share Price to a new one-year high.
What do today’s volume and turnover show for GLAXO?
Ans. GLAXO recorded volume of 11,320 shares and turnover of Rs 3.25 crore in the session. These figures show active traded value on the day when the stock climbed sharply and reached a fresh 52-week peak.
Is GLAXO expensive compared with the Healthcare sector on P/E?
Ans. On the supplied data, GLAXO’s P/E ratio of 170.32 is above the Healthcare sector median of 21 and average of 49.19. That means the stock is trading at a higher earnings multiple than the benchmark set.
How does GLAXO compare with the sector on P/B ratio?
Ans. GLAXO’s P/B ratio is 0.42, which is below the Healthcare sector median of 1.9 and average of 2.6. So, while the stock looks expensive on P/E, it screens lower on price-to-book.
How do GLAXO’s ROE and ROCE compare with sector benchmarks?
Ans. GLAXO has ROE of -2.89 and ROCE of -0.26. Both figures are below the Healthcare sector median levels of 10.92 and 13.29, and also below the sector averages of 15.38 and 17.64.
How large is Glaxosmithkline Pharmaceuticals Ltd. compared with supplied peers?
Ans. Glaxosmithkline Pharmaceuticals Ltd. Market Cap is Rs 45,554.98 crore, far above the supplied peer range of Rs 2,559.68 crore to Rs 2,985.15 crore. That makes GLAXO the clear outlier on size in this comparison.
What should investors monitor next in GLAXO?
Ans. Investors may monitor whether GLAXO holds near its fresh 52-week high, how valuation ratios evolve against Healthcare benchmarks, and whether profitability metrics such as ROE and ROCE improve relative to the supplied sector and peer data.
